Schizophrenia.com

M-RESIST: The first EU mHealth project for patients with treatment-resistant schizophrenia

With a €4 Million budget, the m-RESIST Project (Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia) aims to develop a therapeutic program that draws on the support of mobile devices and actively involves patients with treatment-resistant schizophrenia. This will make them capable of self-managing their illness, as well as support their carers.

Here is more information on best treatment plans for people with treatment-resistant schizophrenia:

Treatment-resistant Schizophrenia: Evidence-based Strategies

Treatment-resistant symptoms complicate the clinical course of schizophrenia, and a large proportion of patients do not reach functional recovery. In consequence, polypharmacy is frequently used in treatment-refractory cases, addressing psychotic positive, negative and cognitive symptoms, treatment-emergent side effects caused by antipsychotics and comorbid depressive or obsessive-compulsive symptoms. To a large extent, such strategies are not covered by pharmacological guidelines which strongly suggest antipsychotic monotherapy. Add-on strategies comprise combinations of several antipsychotic agents and augmentations with mood stabilizers; moreover, antidepressants and experimental substances are applied. Based on the accumulated evidence of clinical trials and meta-analyses, combinations of clozapine with certain second-generation antipsychotic agents and the augmentation of antipsychotics with antidepressants seem recommendable, while the augmentation with mood stabilizers cannot be considered superior to placebo. Forthcoming investigations will have to focus on innovative pharmacological agents, the clinical spectrum of cognitive deficits and the implementation of cognitive behavioral therapy.

1 Like

More information on this project:

Presentation of the first European mHealth project for patients with treatment-resistant schizophrenia

Coordinated by the Fundació TicSalut (Ministry of Health of the Government of Catalonia), the m-RESIST project is financed by European Union Horizon 2020 research and innovation framework program

Today begins the m-RESIST Project (Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia), a European Project aimed to develop a therapeutic program that draws on the support of mobile devices to actively involve patients with treatment-resistant schizophrenia, to make them capable of self-managing their own illness, as well as to support their carers.

Coordinated by the Fundació TicSalut (Ministry of Health of the Government of Catalonia), the m-RESIST project is financed by European Union Horizon 2020 research and innovation framework program, and has a budget of €4 million. m-RESIST relies on the clinical leadership of the Hospital de la Santa Creu i Sant Pau (Barcelona), and the technological leadership of the iMinds Belgian research institute. A total of 12 entities from the public and private sector participate in the project, including hospitals, research centres, universities and companies from 7 European countries.